Twist Bioscience Corp (NASDAQ:TWST) CTO Bill Peck Sells 20,447 Shares
Twist Bioscience Corp (NASDAQ:TWST) CTO Bill Peck sold 20,447 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $28.43, for a total value of $581,308.21. Following the sale, the chief technology officer now directly owns 711,839 shares in the company, valued at approximately $20,237,582.77. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of NASDAQ:TWST traded up $0.69 during trading on Friday, hitting $28.57. 184,609 shares of the stock were exchanged, compared to its average volume of 165,264. The company has a fifty day moving average price of $29.84 and a two-hundred day moving average price of $26.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.18 and a quick ratio of 6.96. Twist Bioscience Corp has a 12-month low of $12.38 and a 12-month high of $35.95.
Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.09). The firm had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $12.51 million. Twist Bioscience had a negative return on equity of 168.45% and a negative net margin of 204.63%. As a group, equities analysts forecast that Twist Bioscience Corp will post -3.8 earnings per share for the current fiscal year.
TWST has been the topic of several research analyst reports. Evercore ISI initiated coverage on Twist Bioscience in a research note on Friday, May 31st. They set an “outperform” rating and a $26.66 price target on the stock. ValuEngine raised Twist Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $26.55.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Further Reading: Dead Cat Bounce
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.